三諾生物(300298.SZ)2019年度淨利降19.25%至2.51億元 擬10派3元
格隆匯4月15日丨三諾生物(300298.SZ)公佈2019年年度報告,營業收入17.78億元,同比增長14.69%;歸屬於上市公司股東的淨利潤2.51億元,同比減少19.25%;歸屬於上市公司股東的扣除非經常性損益的淨利潤2.25億元,同比減少14.98%;基本每股收益0.4445元;擬每10股派發現金股利3元人民幣(含税)。
報告期內,公司圍繞發展戰略和2019年經營計劃有序開展各項工作,加速佈局以患者為中心的全病程管理,強化流程IT建設、強化智能製造和品質製造,堅持持續賦能,推動公司的穩定增長和長遠發展。重點加大核心產品和新產品的市場推廣,加大對醫院市場、基層醫療市場、國際市場以及非血糖檢測產品的開拓力度,不斷提升客户服務和直連用户的能力,進一步豐富公司慢病管理相關的監測產品線。2019年度,公司營業收入增長14.69%。同時,由於一方面公司上年同期完成收購三諾健康管理有限公司64.98%股份,在合併日對原持有股權確認了股權增值部分的投資收益2314.32萬元,另一方面,公司根據《企業會計準則第8號-資產減值》及相關會計政策規定,在2019年度報告中對商譽進行系統性減值測試,經具備證券期貨從業資格的評估機構及審計機構進行評估和審計後確定本期計提商譽減值損失為3418.36萬元;同時,受市場環境及國際銷售等因素影響,公司參股子公司深圳市心諾健康產業投資有限公司2019年處於經營虧損狀態。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.